Current Evidence and Future Directions of PCSK9 Inhibition

Recent scientific and therapeutic advances in proprotein convertase subtilisin kexin type 9 (PCSK9) inhibition have opened a chapter in the management of hypercholesterolemia, especially in patients who are inadequately controlled on or intolerant to statins. The two PCSK9 monoclonal antibodies, evo...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jiaqian Xu, Michael D Shapiro
Formato: article
Lenguaje:EN
Publicado: Radcliffe Medical Media 2021
Materias:
Acceso en línea:https://doaj.org/article/1545b531fe6049699ec45ed8e3e0f060
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!